For instance, HLADRB1*15 is known as a marker of clinical response to immunosuppressive therapy in autoimmune cytopenia.25 Battiwalla et al. reported that the presence of HLA-DRB1*15 in patients with myeloid malignancies was associated with a significantly lower incidence of aGVHD. Here, HLA-DRB1 is linked to myeloid neoplasm.